Research programme: selective estrogen receptor modulators - SRI InternationalAlternative Names: NSC-732011; SR16158; SR16388
Latest Information Update: 03 Feb 2011
At a glance
- Originator SRI International
- Mechanism of Action Estrogen receptor antagonists; Hypoxia-inducible factor 1 inhibitors; Selective estrogen receptor modulators; STAT3 transcription factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer